Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Receives $55.80 Consensus Price Target from Analysts

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has earned an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $55.80.

PTHS has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Oppenheimer lifted their target price on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 24th. Finally, Cantor Fitzgerald assumed coverage on shares of Pelthos Therapeutics in a report on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 target price for the company.

Pelthos Therapeutics Stock Performance

PTHS opened at $25.40 on Friday. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. Pelthos Therapeutics has a 52-week low of $16.50 and a 52-week high of $37.50. The firm has a market cap of $88.39 million, a price-to-earnings ratio of -1.23 and a beta of 3.10. The stock’s fifty day moving average is $26.93.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) EPS for the quarter. The business had revenue of $10.91 million for the quarter. On average, research analysts predict that Pelthos Therapeutics will post -12.63 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Todd C. Davis purchased 35,948 shares of the stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $27.82 per share, for a total transaction of $1,000,073.36. Following the completion of the acquisition, the director owned 75,834 shares of the company’s stock, valued at approximately $2,109,701.88. This represents a 90.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 1,638 shares of company stock worth $43,107 in the last three months. 12.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pelthos Therapeutics

Hedge funds have recently modified their holdings of the company. Knott David M Jr increased its holdings in Pelthos Therapeutics by 9.3% in the 1st quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after purchasing an additional 1,792 shares in the last quarter. Geode Capital Management LLC raised its position in Pelthos Therapeutics by 31.9% in the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after purchasing an additional 3,295 shares during the last quarter. Persistent Asset Partners Ltd boosted its stake in shares of Pelthos Therapeutics by 150.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares in the last quarter. Pale Fire Capital SE grew its holdings in shares of Pelthos Therapeutics by 59.5% during the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock worth $271,000 after purchasing an additional 4,819 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in shares of Pelthos Therapeutics during the fourth quarter worth about $343,000. Institutional investors and hedge funds own 77.96% of the company’s stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).